AR018593A1 - COMPUESTOS TRICICLICOS SUSTITUIDOS, FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE, USO DE DICHO COMPUESTO PARA FABRICAR UN MEDICAMENTO uTIL PARA INHIBIR SELECTIVAMENTE SPLA2 Y ALIVIAR EFECTOS PATOLoGICOS DE ENFERMEDADES RELACIONADAS - Google Patents
COMPUESTOS TRICICLICOS SUSTITUIDOS, FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE, USO DE DICHO COMPUESTO PARA FABRICAR UN MEDICAMENTO uTIL PARA INHIBIR SELECTIVAMENTE SPLA2 Y ALIVIAR EFECTOS PATOLoGICOS DE ENFERMEDADES RELACIONADASInfo
- Publication number
- AR018593A1 AR018593A1 ARP990101771A ARP990101771A AR018593A1 AR 018593 A1 AR018593 A1 AR 018593A1 AR P990101771 A ARP990101771 A AR P990101771A AR P990101771 A ARP990101771 A AR P990101771A AR 018593 A1 AR018593 A1 AR 018593A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- substituted
- hydrogen
- carbon
- sulfur
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 230000001575 pathological effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 230000002452 interceptive effect Effects 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 239000011593 sulfur Substances 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 102000005473 Secretory Phospholipases A2 Human genes 0.000 abstract 1
- 108010031873 Secretory Phospholipases A2 Proteins 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describen nuevos compuestos tricíclicos y el uso de los mismos para inhibir la liberacion de ácidos grasos inducida por sPLA2 para el tratamientode trastornos como el choque séptico. Dichos compuestos tienen la formula (I), en la que: Z es ciclohexenilo o fenilo, R20 se selecciona de grupo (a), (b)y (c), donde: (a) es alquilo C5-20, alquenilo C5-20, alquinilo C-5-20, radicales carbocíclicos o radicales heterocíclicos, o (b) es un miembro de (a)sustituido con uno o más sustituyentes no interferentes, seleccionados independientemente; o (c) es el grupo -(L)-R80; siendo -(L)- un grupo de uniondivalente de 1 a 12 átomos, seleccionados de carbono, hidrogeno, oxígeno, nitrogeno y azufre; seleccionándose la combinacion de átomos en -(L)- delgrupo compuesto por (i) solo carbono e hidrogeno, (ii) solo azufre, (iii) solo un oxígeno, (iv) solo uno o dos nitrogenos e hidrogeno, (v) carbono, hidrogeno ysolo un azufre, y (vi) un carbono, hidrogeno y solo oxígeno; y siendo R80 un grupo seleccionado de (a) o (b); R21 es un sustituyente no interferente en elque f es 1-3; R1 es -NHNH2, -NH2 o -CONH2; R2 se selecciona del grupo formado por -OH y -O(CH2)tR5, donde R5 es H, -CN, -NH2, -CONH2, -CONR9R10, -NHSO2R15,-CONHSO2R15, siendo R15 -alquilo C1-6 o -CF3, fenilo o fenilo sustituido con -CO2H o -CO2-alquilo C1-4; y -(La)- (grupo ácido), siendo -(La)-un grupo de unionde ácido que tiene una longitud de grupo de union de ácido de 1 a 7, y t es 1-5; R3 se selecciona de sustituyentes no interferentes, radicales carbocíclicos,carbocíclicos sustituidos con sustituyentes no interferentes, radicales heterocíclicos y radicales heterocíclicos sustituidos con sustituyentes nointerferentes; o uno de sus racematos, solvatos, tautomeros, isomeros opticos, derivados profármacos o sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6232898A | 1998-04-17 | 1998-04-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR018593A1 true AR018593A1 (es) | 2001-11-28 |
Family
ID=22041763
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990101770A AR018186A1 (es) | 1998-04-17 | 1999-04-16 | Compuestos de carbazoly de 1,2,3,4-tetrahidrocarbazol sustituidos, utiles como inhibidores de la liberacion de acidos grasos mediada por spla2,procedimiento para prepararlos; compuestos intermediarios de aplicacion en dichos procedimientos; composiciones farmaceuticas que comprenden dichos compuesto |
| ARP990101771A AR018593A1 (es) | 1998-04-17 | 1999-04-16 | COMPUESTOS TRICICLICOS SUSTITUIDOS, FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE, USO DE DICHO COMPUESTO PARA FABRICAR UN MEDICAMENTO uTIL PARA INHIBIR SELECTIVAMENTE SPLA2 Y ALIVIAR EFECTOS PATOLoGICOS DE ENFERMEDADES RELACIONADAS |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990101770A AR018186A1 (es) | 1998-04-17 | 1999-04-16 | Compuestos de carbazoly de 1,2,3,4-tetrahidrocarbazol sustituidos, utiles como inhibidores de la liberacion de acidos grasos mediada por spla2,procedimiento para prepararlos; compuestos intermediarios de aplicacion en dichos procedimientos; composiciones farmaceuticas que comprenden dichos compuesto |
Country Status (30)
| Country | Link |
|---|---|
| EP (2) | EP0952149B1 (es) |
| JP (2) | JPH11322713A (es) |
| KR (2) | KR100586761B1 (es) |
| CN (1) | CN1149193C (es) |
| AR (2) | AR018186A1 (es) |
| AT (2) | ATE268756T1 (es) |
| AU (2) | AU753547B2 (es) |
| BR (2) | BR9902365A (es) |
| CA (2) | CA2269262A1 (es) |
| CO (2) | CO5011054A1 (es) |
| CZ (2) | CZ137099A3 (es) |
| DE (2) | DE69917833T2 (es) |
| DK (1) | DK0950657T3 (es) |
| DZ (1) | DZ2769A1 (es) |
| EA (2) | EA002347B1 (es) |
| ES (2) | ES2222663T3 (es) |
| HU (2) | HUP9901221A3 (es) |
| ID (2) | ID23761A (es) |
| IL (2) | IL129485A0 (es) |
| NO (2) | NO312240B1 (es) |
| NZ (3) | NZ507564A (es) |
| PE (2) | PE20000432A1 (es) |
| PL (2) | PL332565A1 (es) |
| PT (1) | PT950657E (es) |
| SG (2) | SG81977A1 (es) |
| SI (1) | SI0950657T1 (es) |
| TR (2) | TR199900843A2 (es) |
| TW (1) | TWI238160B (es) |
| YU (2) | YU18999A (es) |
| ZA (2) | ZA992772B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610728B2 (en) * | 1997-08-28 | 2003-08-26 | Eli Lilly And Company | Method for treatment of non-rheumatoid arthritis |
| DZ2769A1 (fr) * | 1998-04-17 | 2003-12-01 | Lilly Co Eli | Composés tricycliques substitués. |
| CA2358492A1 (en) * | 1998-12-21 | 2000-06-29 | Eli Lilly And Company | Combination therapy for the treatment of sepsis |
| DE60032774D1 (de) * | 1999-07-19 | 2007-02-15 | Lilly Co Eli | Spla2 inhibitoren |
| US6706752B1 (en) | 1999-07-19 | 2004-03-16 | Eli Lilly And Company | sPLA2 inhibitors |
| DE60130891T2 (de) * | 2000-06-29 | 2008-07-17 | Anthera Pharmaceuticals Inc., San Mateo | Heilmittel für krebs |
| WO2002000256A1 (fr) * | 2000-06-29 | 2002-01-03 | Shionogi & Co., Ltd. | Remedes contre la cirrhose |
| WO2002000257A1 (en) * | 2000-06-29 | 2002-01-03 | Shionogi & Co., Ltd. | Remedies for alzheimer's disease |
| CN1450893A (zh) * | 2000-07-14 | 2003-10-22 | 伊莱利利公司 | 治疗脓毒症的方法 |
| AU2002239263A1 (en) | 2000-12-18 | 2002-07-01 | Eli Lilly And Company | Tetracyclic carbazole derivates and their use as spla2 inhibitors |
| DE60218155D1 (de) | 2001-03-28 | 2007-03-29 | Lilly Co Eli | Substituierte carbazole als inhibitoren von spla2 |
| AUPS282602A0 (en) | 2002-06-07 | 2002-06-27 | Garvan Institute Of Medical Research | Method of inhibiting cell proliferation |
| DE10249055A1 (de) | 2002-10-22 | 2004-05-06 | Bayer Cropscience Ag | 2-Phenyl-2-substituierte-1,3-diketone |
| JO3598B1 (ar) | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
| EP1988098A1 (en) * | 2007-04-27 | 2008-11-05 | AEterna Zentaris GmbH | Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors |
| WO2009119534A1 (ja) | 2008-03-26 | 2009-10-01 | 第一三共株式会社 | 新規テトラヒドロイソキノリン誘導体 |
| AU2009233711B2 (en) | 2008-04-09 | 2015-02-12 | Infinity Pharmaceuticals, Inc | Inhibitors of fatty acid amide hydrolase |
| US8580795B2 (en) | 2009-01-22 | 2013-11-12 | Orchid Chemicals & Pharmaceuticals Limited | Heterocyclic compounds as phosphodiesterase inhibitors |
| WO2010118155A1 (en) | 2009-04-07 | 2010-10-14 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| WO2010118159A1 (en) | 2009-04-07 | 2010-10-14 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| BR112012019120A2 (pt) | 2010-02-03 | 2016-06-28 | Infinity Pharmaceuticais Inc | forma sólida, composição farmacêutica, método de preparação do composto 1, método de tratamento de uma condição mediada por faah |
| AR088377A1 (es) | 2011-10-20 | 2014-05-28 | Siena Biotech Spa | Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta |
| CN102816107B (zh) * | 2012-08-20 | 2015-06-03 | 东南大学 | 咔唑衍生物及其制备方法与用途 |
| WO2014083163A1 (en) | 2012-11-30 | 2014-06-05 | Ge Healthcare Limited | Zinc halide mediated cyclization process leading to tricyclic indoles |
| RU2015118217A (ru) | 2012-11-30 | 2017-01-11 | ДжиИ ХЕЛТКЕР ЛИМИТЕД | Способ кристаллизации трициклических индольных производных |
| WO2016116527A1 (de) * | 2015-01-20 | 2016-07-28 | Cynora Gmbh | Organische moleküle, insbesondere zur verwendung in optoelektronischen bauelementen |
| CN108707104A (zh) * | 2018-08-07 | 2018-10-26 | 北京恒信卓元科技有限公司 | 2-氯-1h-咔唑-1,4(9h)-二酮的合成方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3579534A (en) * | 1969-05-09 | 1971-05-18 | American Cyanamid Co | Tetrahydrocarbazolecarboxylates |
| US3979391A (en) * | 1972-11-22 | 1976-09-07 | Sterling Drug Inc. | 1,2,3,4-Tetrahydrocarbazoles |
| US3939177A (en) * | 1972-11-22 | 1976-02-17 | Sterling Drug Inc. | 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles |
| PT95692A (pt) * | 1989-10-27 | 1991-09-13 | American Home Prod | Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase |
| US5420289A (en) * | 1989-10-27 | 1995-05-30 | American Home Products Corporation | Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase |
| JPH06509087A (ja) * | 1991-07-05 | 1994-10-13 | メルク シヤープ エンド ドーム リミテツド | 芳香族化合物、それらを含む医薬組成物、及び治療におけるそれらの使用 |
| MY110227A (en) * | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| IL109309A (en) * | 1993-04-16 | 2000-06-29 | Lilly Co Eli | 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them |
| IL109311A0 (en) * | 1993-04-16 | 1994-07-31 | Lilly Co Eli | 1H-indole-3-acetamide sPla2 inhibitors |
| EP0749962B1 (en) * | 1995-06-23 | 2000-11-02 | Eli Lilly And Company | 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles |
| DE69614232T2 (de) * | 1995-12-13 | 2002-01-10 | Eli Lilly And Co., Indianapolis | Naphthyl-Acetamide als sPLA2-Inhibitoren |
| KR20000049210A (ko) * | 1996-10-30 | 2000-07-25 | 피터 지. 스트링거 | 치환된 트리시클릭류 |
| AU9664198A (en) * | 1997-09-26 | 1999-04-23 | Eli Lilly And Company | Method for the treatment of cystic fibrosis |
| JP2001522884A (ja) * | 1997-11-14 | 2001-11-20 | イーライ・リリー・アンド・カンパニー | アルツハイマー病の処置方法 |
| DZ2769A1 (fr) * | 1998-04-17 | 2003-12-01 | Lilly Co Eli | Composés tricycliques substitués. |
-
1999
- 1999-04-14 DZ DZ990069A patent/DZ2769A1/xx active
- 1999-04-15 IL IL12948599A patent/IL129485A0/xx unknown
- 1999-04-15 ID IDP990341D patent/ID23761A/id unknown
- 1999-04-15 IL IL12948399A patent/IL129483A0/xx unknown
- 1999-04-15 ID IDP990340D patent/ID23287A/id unknown
- 1999-04-16 ZA ZA9902772A patent/ZA992772B/xx unknown
- 1999-04-16 PL PL99332565A patent/PL332565A1/xx not_active Application Discontinuation
- 1999-04-16 AR ARP990101770A patent/AR018186A1/es not_active Application Discontinuation
- 1999-04-16 BR BR9902365-2A patent/BR9902365A/pt not_active IP Right Cessation
- 1999-04-16 JP JP11109629A patent/JPH11322713A/ja not_active Withdrawn
- 1999-04-16 AR ARP990101771A patent/AR018593A1/es active IP Right Grant
- 1999-04-16 SG SG9901869A patent/SG81977A1/en unknown
- 1999-04-16 EP EP99302941A patent/EP0952149B1/en not_active Expired - Lifetime
- 1999-04-16 HU HU9901221A patent/HUP9901221A3/hu unknown
- 1999-04-16 PL PL99332566A patent/PL332566A1/xx not_active Application Discontinuation
- 1999-04-16 CZ CZ991370A patent/CZ137099A3/cs unknown
- 1999-04-16 DE DE69917833T patent/DE69917833T2/de not_active Expired - Lifetime
- 1999-04-16 NZ NZ507564A patent/NZ507564A/xx unknown
- 1999-04-16 SI SI9930650T patent/SI0950657T1/xx unknown
- 1999-04-16 NZ NZ335251A patent/NZ335251A/xx unknown
- 1999-04-16 CN CNB991079574A patent/CN1149193C/zh not_active Expired - Fee Related
- 1999-04-16 YU YU18999A patent/YU18999A/sh unknown
- 1999-04-16 NO NO19991822A patent/NO312240B1/no not_active IP Right Cessation
- 1999-04-16 DE DE69918590T patent/DE69918590T2/de not_active Expired - Lifetime
- 1999-04-16 TR TR1999/00843A patent/TR199900843A2/xx unknown
- 1999-04-16 AT AT99302941T patent/ATE268756T1/de not_active IP Right Cessation
- 1999-04-16 DK DK99302967T patent/DK0950657T3/da active
- 1999-04-16 YU YU19199A patent/YU19199A/sh unknown
- 1999-04-16 EA EA199900301A patent/EA002347B1/ru not_active IP Right Cessation
- 1999-04-16 ES ES99302941T patent/ES2222663T3/es not_active Expired - Lifetime
- 1999-04-16 ES ES99302967T patent/ES2226286T3/es not_active Expired - Lifetime
- 1999-04-16 PT PT99302967T patent/PT950657E/pt unknown
- 1999-04-16 PE PE1999000314A patent/PE20000432A1/es not_active Application Discontinuation
- 1999-04-16 SG SG9901681A patent/SG81976A1/en unknown
- 1999-04-16 KR KR1019990013438A patent/KR100586761B1/ko not_active Expired - Fee Related
- 1999-04-16 PE PE1999000320A patent/PE20000476A1/es not_active Application Discontinuation
- 1999-04-16 BR BR9901279-0A patent/BR9901279A/pt not_active IP Right Cessation
- 1999-04-16 CO CO99022897A patent/CO5011054A1/es unknown
- 1999-04-16 EP EP99302967A patent/EP0950657B1/en not_active Expired - Lifetime
- 1999-04-16 NO NO19991821A patent/NO314400B1/no not_active IP Right Cessation
- 1999-04-16 AU AU23819/99A patent/AU753547B2/en not_active Ceased
- 1999-04-16 CZ CZ991369A patent/CZ136999A3/cs unknown
- 1999-04-16 JP JP15240099A patent/JP4435330B2/ja not_active Expired - Fee Related
- 1999-04-16 HU HU9901220A patent/HUP9901220A3/hu unknown
- 1999-04-16 KR KR1019990013436A patent/KR19990083232A/ko not_active Withdrawn
- 1999-04-16 ZA ZA9902771A patent/ZA992771B/xx unknown
- 1999-04-16 CA CA002269262A patent/CA2269262A1/en not_active Abandoned
- 1999-04-16 CO CO99022884A patent/CO5031247A1/es unknown
- 1999-04-16 EA EA199900303A patent/EA002816B1/ru not_active IP Right Cessation
- 1999-04-16 CA CA002269246A patent/CA2269246C/en not_active Expired - Fee Related
- 1999-04-16 TW TW088106130A patent/TWI238160B/zh not_active IP Right Cessation
- 1999-04-16 NZ NZ335253A patent/NZ335253A/xx unknown
- 1999-04-16 AT AT99302967T patent/ATE271037T1/de active
- 1999-04-16 AU AU23817/99A patent/AU753436B2/en not_active Ceased
- 1999-04-16 TR TR1999/00853A patent/TR199900853A2/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5700824A2 (es) | Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| YU19199A (sh) | Supstituisani tricikli | |
| AR018185A1 (es) | Compuestos triciclicos substituidos utiles como inhibidores de la liberacion de acidos grasos mediada por spla2 en mamiferos y uso de dichos compuestos enla fabricacion de composiciones para aliviar los efectos patologicos de enfermedades relacionadas con spla2 | |
| AR059895A1 (es) | Derivados biciclicos de acidos carboxilicos que resultan de utilidad para tratar trastornos metabolicos | |
| AR071739A1 (es) | Inhibidores de transcriptasa reversa | |
| AR008377A1 (es) | Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto | |
| AR016523A1 (es) | Compuestos de indol como agentes anti-inflamatorios/analgesicos, composiciones farmaceuticas que los contienen y procedimiento de tratamiento | |
| ES2530545T3 (es) | Compuestos tricíclicos inhibidores de la PI3K y métodos de uso | |
| AR052887A1 (es) | Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa | |
| ECSP056222A (es) | Derivados de indazolil(indolil)maleimida sustituidoscomo inhibidores de cinasa | |
| UY29437A1 (es) | Nuevos antagonistas de cgrp | |
| BR9915895A (pt) | Composto, uso do mesmo, processo para prepará-lo, método para o tratamento de um mamìfero, incluindo o homem, de condições resultantes de nìveis de circulação elevados de apob-100, e, composição farmacêutica | |
| MXPA03002839A (es) | Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7. | |
| ES2253568T3 (es) | Compuestos heterociclicos para el uso en el tratamiento de los trastornos de las vias urinarias. | |
| CO4920250A1 (es) | Compuestos heterociclicos utiles en la inhibicion de la spla2 | |
| CO5040004A1 (es) | 2-4-diamino-1,3,5-triazinas, su preparacion y empleo como herbicidas y fitorreguladores | |
| MX2023015490A (es) | Inhibidores de las transglutaminasas. | |
| AR019256A1 (es) | Utilizacion de derivados tetraciclo[6-6-2-0(2.27).0(9.14)] hexadeca-2(7), 3, 5, 9(14), 10,12-hexaeno, para la preparacion de preparados farmaceuticos conaccion inhibitoria de la fosfolipasa, los referidos derivados y preparado farmaceutico que contiene por lo menos a uno de dichos derivados | |
| AR045100A1 (es) | Pirimidinas sustituidas, procedimiento para su obtencion y su uso en productos pesticidas | |
| PE20240822A1 (es) | Inhibidores de vmat2 y metodos de uso | |
| MX2020011020A (es) | Compuestos farmaceuticamente efectivos que inhiben selectivamente las isoformas de miosina 2. | |
| CL2024003427A1 (es) | Derivados de pirrolidinona como inhibidores de quinasa inductora de nf-kb. | |
| AR108535A1 (es) | Derivados de tetrahidropirano y tiopirano que tienen actividad multimodal contra el dolor | |
| AR044295A1 (es) | Composiciones nematicidas y metodos | |
| ES2187597T3 (es) | Derivados de la piperidinilmetiloxazolidin-2-ona, su obtencion y su empleo como compuestos eficaces para el sistema nervioso central. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |